drugset / Trial / NCT00750386
Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas
Phase 1/2
Completed
50 enrolled
Hellenic Oncology Research Group
University Hospital of Crete · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This trial will determine the feasibility and toxicity of dose intense (every 2 weeks) of paclitaxel+carboplatin combination following cytoreductive surgery in patients with stage Ic-IV ovarian cancer.
Timeline
- Start
- 2008-01
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |